[1]Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome[J]. J Clin Endocrinol Metab, 2008,93:4183-4197. [2]Noordam C, Höybye C, Eiholzer U. Prader-Willi syndr-ome and hypogonadism: a review article[J]. Int J Mol Sci, 2021,22:2705. doi: 10.3390/ijms22052705. [3]Kido Y, Sakazume S, Abe Y, et al. Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: an observational study[J]. Am J Med Genet A, 2013,161:2167-2173. [4]Donze SH, Kuppens RJ, Bakker NE, et al. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial[J]. Clin Endocrinol (Oxf), 2018,88:806-812. [5]Colmou A. Estrogens and vascular thrombosis[J]. Soins Gynecol Obstet Pueric Pediatr, 1982,16:39-41. [6]Traish AM. Benefits and health implications of testoster-one therapy in men with testosterone deficiency[J]. Sex Med Rev, 2018,6:86-105. [7]Hoover R, Fraumeni JJ. Drug-induced cancer[J]. Cancer, 1981,47:1071-1080. [8]Eiholzer U, Grieser J, Schlumpf M, et al. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome[J]. Horm Res, 2007,68:178-184. [9]Morgentaler A, Miner MM, Caliber M, et al. Testosterone therapy and cardiovascular risk: advances and controver-sies[J]. Mayo Clin Proc, 2015,90:224-251. [10]Hartmann BW, Huber JC. The mythology of hormone replacement therapy[J]. Br J Obstet Gynaecol, 1997,104:163-168. [11]Bakker NE, Kuppens RJ, Siemensma EP, et al. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment[J]. J Clin Endocrinol Metab, 2015,100:1609-1618. |